Tolerability of spironolactone in patients with chronic heart failure - A cautionary message

British Journal of Clinical Pharmacology

Volumn 58, Issue 5, 2004, Pages 554-557

  Witham, Miles D ^a   Gillespie, Neil D ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aged; Congestive; Heart failure; Spironolactone

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE;

AGED; CHRONIC DISEASE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HEADACHE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH PAIN; TINNITUS; TREATMENT OUTCOME; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; CHRONIC DISEASE; COHORT STUDIES; CREATININE; FEMALE; GUIDELINE ADHERENCE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; MALE; PRACTICE GUIDELINES; RISK FACTORS; SPIRONOLACTONE;

EID: 9144220832     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02187.x     Document Type: Review

References (9)

1. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
2. Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail 2002; 4: 91-8.
3. King D. Diagnosis and management of heart failure in the elderly. Postgrad Med J 1996; 72: 577-80.
4. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. Br Med J 2003; 327: 147-9.
5. Anton C, Cox AR, Watson RD, Ferner RE. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther 2003; 28: 285-7.
6. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. Br Med J 2003; 327: 1141-2.
7. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001; 85: E8.
8. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41: 211-14.
9. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 2001; 110: 438-41.